Enoximone cas 77671-31-9

Enoximone is an inotropic vasodilating agent and a selective and orally active phosphodiesterase III (PDE3) inhibitor with an IC50 of 5.9 μM. Enoximone induces vasodilatation and increases intracellular levels of cAMP by inhibiting cGMP-inhibited PDE. Enoximone also exhibits PDE4 inhibitory effect with an IC50 of 21.1 μM for myocardial PDE4A. Enoximone has the potential for congestive heart failure research and has bronchodilatory, antiasthma and anti-inflammatory effects.

PDE Inhibitors Related Products:

Roflumilast; Tadalafil; Pimobendan; GSK256066; Mardepodect; Apremilast; Milrinone; Avanafil; Ziritaxestat; Ibudilast; Balipodect; PF8380; Deltarasin; Anagrelide hydrochloride; Enpp-1-IN-1; Crisaborole; CP671305; Sildenafil citrate; Cilomilast

[1]. Jan Beute, et al. A Pathophysiological Role of PDE3 in Allergic Airway Inflammation. JCI Insight. 2018 Jan 25;3(2):e94888.

[2]. R C Dage, et al. Pharmacology and Pharmacokinetics of Enoximone. Cardiology. 1990;77 Suppl 3:2-13; discussion 27-33.